• 31 May 2024
• Admin
• News Article

US FDA Approves First Interchangeable Biosimilar to Treat Certain Rare Diseases

Overview

The US Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris.

The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; and the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

US FDA Granted the Approval of Bkemv to Amgen Inc.

Words from Director: Therapeutic Biologics

• "Many rare conditions are life-threatening, and many do not have treatments," said Sarah Yim, director of the office of therapeutic biologics and biosimilars in the US FDA's Center for Drug Evaluation and Research. 
• "The US FDA is committed to help facilitate the development of safe and effective interchangeable biosimilar treatments that can expand access for individuals with rare diseases whose current treatment options are limited."

PNH and aHUS: Rare Diseases

• A disease is considered rare if it affects fewer than 200,000 people in the US. 
• The conditions PNH and aHUS are rare diseases characterized by the breakdown of red blood cells. 
• PNH results in anemia (low red blood cells), thrombosis (blood clots), pancytopenia (low counts of red blood cells, white blood cells, and platelets) and dark urine, while aHUS results in anemia, thrombocytopenia (low platelets) and kidney failure.

Bkemv

• Bkemv is a monoclonal antibody that binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system. 
• This binding prevents the breakdown of red blood cells in the bloodstream (intravascular hemolysis) in patients with PNH and aHUS.

Warnings for Bkemv

• Bkemv, like Soliris, has a Boxed Warning that states that eculizumab products increase the risk of serious and life-threatening meningococcal infections caused by Neisseria meningitidis, the bacteria that causes meningitis and other potentially severe infections. 
• Patients should have completed meningococcal vaccination before starting Bkemv or Soliris, be monitored for early signs and symptoms of meningococcal infections and undergo further evaluation immediately if signs of infection develop.

Adverse Effects

• As an interchangeable biosimilar, Bkemv is highly similar with no clinically meaningful differences to Soliris. 
• Bkemv has the same safety warnings and is expected to have the same adverse reactions as Soliris. 
• The most frequently reported adverse reactions in the PNH randomized trial for Soliris (=10% overall and greater than placebo) are headache, nasopharyngitis (common cold), back pain and nausea. 
• The most frequently reported adverse reactions in aHUS single arm prospective trials for Soliris (=20%) are headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, swelling of lower legs or hands, nausea, urinary tract infections and fever.

Bkemv Availability

• Bkemv is available only through a restricted program called the Bkemv Risk Evaluation and Mitigation Strategy (REMS). 
• A REMS is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.

Bkemv is the 53rd approved biosimilar in the US. The US FDA has approved 13 of these as interchangeable biosimilars.

Interchangeable Biosimilar

• An interchangeable biosimilar is a biosimilar that has been shown to meet other requirements under the law and may be substituted for the reference product without consulting the prescriber. 
• The substitution may occur at the pharmacy, subject to state pharmacy laws which vary by state, a practice commonly called "pharmacy-level substitution" — similar to generic drug substitution for brand name drugs. All biological products are approved only after meeting the FDA's rigorous approval standards. 
• This means health care providers and patients can expect the same safety and effectiveness from both a biosimilar and an interchangeable biosimilar, just as they would for a reference product.

Approvals

The approval of biosimilar and interchangeable biosimilar products furthers the US FDA's longstanding commitment to support a competitive marketplace for biological products and increase patient access to more affordable treatment options.